WO2000032803A2 - Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations - Google Patents
Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations Download PDFInfo
- Publication number
- WO2000032803A2 WO2000032803A2 PCT/FR1999/002995 FR9902995W WO0032803A2 WO 2000032803 A2 WO2000032803 A2 WO 2000032803A2 FR 9902995 W FR9902995 W FR 9902995W WO 0032803 A2 WO0032803 A2 WO 0032803A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- amino
- transfer agents
- mmol
- hydrophilic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Definitions
- the present invention relates to new transfer agents, the compositions containing them and their uses for the in vitro, in vivo or ex vivo transfer of nucleic acids into cells.
- nucleic acids into cells have become a basic technique with many biotechnological applications. It may be the transfer of nucleic acids into cells in vitro, for example for the production of recombinant proteins, or in the laboratory for the study of the regulation of gene expression, the cloning of genes or any other manipulation involving DNA. It can also involve the transfer of nucleic acids into cells in vivo, for example for the production of vaccines, labeling studies or also therapeutic approaches. It may also involve the transfer of genes into cells taken from an organism, with a view to their subsequent re-administration, for example for the creation of transgenic animals.
- lipids comprising a quaternary ammonium group (for example DOTMA, DOTAP, DMRIE, DLRIE, etc.), lipopolyamines such as, for example, DOGS, DC-Chol or the disclosed lipopolyamines in patent application WO 97/18185, lipids combining both a quaternary ammonium group and a polyamine such as DOSPA, or alternatively lipids comprising various other cationic entities, in particular amidinium groups (for example ADPDE, ADODE or the lipids of patent application WO 97/31935).
- the structural diversity of cationic lipids partly reflects the observation of the structure-activity relationship.
- charge ratio means the ratio of the positive charges of the transfer agent to the negative charges of DNA. This ratio is often expressed in nmoles of transfer agent per ⁇ g of DNA.
- transfecting agents developed by the applicant, and which are the subject of the present invention, propose to solve. Indeed, their particular structure forms a hydrophobic anchor linked on the one hand to a polycation which allows the formation of complexes with nucleic acids and on the other hand to at least one hydrophilic head which makes it possible to decrease the apparent overall charge density of these transfecting agents with respect to lipids or cationic polymers conventionally used in non-viral transfection.
- the presence of at least one hydrophilic head creates a sort of “charge screen” by reducing the zeta potential of the complexes formed with the nucleic acid.
- said complexes appear less cationic to the organism, with the beneficial consequences which result therefrom.
- the transfecting agents according to the present invention are particularly advantageous from a physicochemical point of view since they are particularly stable when they are brought into contact with nucleic acids at low charge ratios.
- a first object of the invention relates to new nucleic acid transfer agents which comprise a hydrophobic spacer linked chemically on the one hand to a polycation and on the other hand to at least one hydrophilic substituent.
- the hydrophobic spacer has a dual function. On the one hand, it allows passage through cell membranes, and on the other hand, it makes the complexes formed with nucleic acids viable in biological medium. Indeed, the hydrophobic spacer creates a physical constraint on the complexes which makes it possible to protect the nucleic acids from the external environment. The hydrophobicity necessary for the complexes to be viable can be easily determined by a person skilled in the art, by application of ordinary research methods or by the usual method of trial and error. Finally, the presence of the hydrophilic substituent (s) makes it possible to reduce the zeta potential of the complexes formed, which causes said less cationic complexes to appear in the outside environment.
- polycation is a linear or branched polycationic molecule capable of associating with nucleic acids.
- association with nucleic acid means any type of bond, such as, for example, covalent bonds, electrostatic, ionic interactions, hydrogen bridges, etc.
- the polycation is a linear or branched polyamine , each amino group being separated by one or more methylene groups.
- the polyamine may also be substituted by other cationic functions, for example amidinium or guanidinium groups, cyclic guanidines, etc.
- the polycation represents a polyamine of general formula (II) in which :
- R - R ,, R 2 and R 3 represent independently of each other a hydrogen atom or a group (CH 2 ) q NR'R "with q an integer which can vary from 1 to 6, this independently between the different groups R réelleR, and R 3 , it being understood that at least one of R ,, R 2 and R 3 is different from a hydrogen atom,
- R - R 'and R independently of one another represent a hydrogen atom or a group (CH 2 ) q NH 2 with q defined as above,
- - m represents an integer between 1 and 6, and - n and p independently represent whole numbers between 0 and 6, with when n is greater than or equal to 2, m can take values and R 3 have different meanings within the general formula (II), and when n is equal to 0, at least one of the substituents R, and R 2 is different from a hydrogen atom.
- polycations can also be chosen from spermine, spermidine, cadaverine, putrescine, hexamethylenetetramine (hexamine), methacrylamidopropyl-trimethylammonium chloride (AMBTAC), 3-acrylamido-3-methylbutyltrimethylammonium chloride ( AMBTAC), polyvinylamines, polyethyleneimines, or even ionenes.
- the hydrophobic spacer can take very varied structures as long as it provides sufficient hydrophobicity to allow protection of the nucleic acids and passage through the membranes. This sufficient hydrophobicity can be determined by a person skilled in the art by applying research methods. ordinary.
- the hydrophobic spacer consists of 2 or 3 linear fatty hydrocarbon chains (that is to say between 10 and 20 carbon atoms per chain, and preferably 12, 14, 15, 16, 17, or 18 carbon atoms per chain, each chain can be of different length).
- the hydrophobic spacer consists of a very long linear fatty hydrocarbon chain, that is to say comprising between 20 and 50 carbon atoms, and preferably between 40 and 50 carbon atoms and even more preferably between 44 and 50 carbon atoms).
- Suitable hydrophilic substituents are for example chosen from hydroxy, amino substituents, polyols, sugars, or also hydrophilic peptides.
- Polyol is understood to mean any linear, branched or cyclic hydrocarbon molecules comprising at least two hydroxy functions.
- glycerol ethylene glycol, propylene glycol, tetritols, pentitols, cyclic pentitols (or quercitols), hexitols such as mannitol, sorbitol, dulcitols, cyclic hexitols or inositols etc.
- the transfer agents according to the invention comprise at least one hydrophilic substituent which is a sugar.
- the term “sugar” means any molecule consisting of one or more saccharides. Mention may be made, by way of example, of sugars such as pyranoses and furanoses, for example glucose, mannose, rhamnose, galactose, fructose, or even maltose, lactose, saccharose, sucrose, fucose, cellobiose, allose, laminarabiose, gentiobiose, sophorose, melibiose etc.
- the sugar or sugars are chosen from glucose, mannose, rhamnose, galactose, fructose, lactose , sucrose and cellobiose.
- it can also be so-called "complex" sugars, that is to say several sugars covalently coupled to each other, each sugar preferably being chosen from the list cited above.
- suitable polysaccharides mention may be made of dextran, ⁇ -amylose, amylopectin, fructans. mannans, xylans and arabinans.
- Some sugars preferred can also interact with cellular receptors, such as certain types of lectins.
- transfer agents according to the invention can be represented by the general formula (I):
- - Z represents a hydrogen atom or a fluorine atom, the different Z being independent of each other, and - either x and y, independently of one another, represent integers between 10 and 22 inclusive, and X and Y, independently of one another, represent a hydrogen atom, an -OAlk group where Alk represents a straight or branched alkyl containing 1 to 4 carbon atoms, a hydroxy group, an amino group, a polyol, a sugar, a hydrophilic or non-hydrophilic peptide, or an oligonucleotide, it being understood that at least one of the substituents X and Y represents a hydrophilic group chosen from hydroxy, amino, polyols, sugars, or hydrophilic peptides,
- x is equal to 0 or 1
- y is an integer between 20 and 50
- X is either a hydrogen atom or a group -OAlk where Alk represents a straight or branched alkyl containing 1 to 4 carbon atoms
- Y is a hydrophilic group chosen from hydroxy, amino, polyols, sugars, or hydrophilic peptides.
- polycation the polyols and the sugars of the general formula (I) are as defined above.
- x and y are defined in the general formula (I) so as to take any value between 10 and 22 inclusive or between 20 and 50 inclusive depending on the case.
- x and y independently of one another, are between 12 and 18 inclusive. More preferably, x and y are, independently of one another, 14, 15, 16, 17 or 18.
- y is preferably between 30 and 50, or between 40 and 50. More preferably, it is between 44 and 50.
- oligonucleotide means chains containing one or more nucleotides, deoxynucleotides, ribonucleotides and / or deoxyribonucleotides which are monomeric units which differ from one another by the presence of bases which can be chosen from adenine, guanine, cytosine, thymidine or uracil [see Lehninger Biochemistry, Flammarion Médecine Sciences, 2nd edition, p. 305-329]. Owing to their property in forming base pairs, oligonucleotides are widely used in molecular biology, for example as linkers or as probes.
- the oligonucleotides can also be used in the form of conjugates, that is to say coupled to one or more other molecules having distinct properties.
- conjugates that is to say coupled to one or more other molecules having distinct properties.
- conjugates described in Bioconjugate Chemistry [John Goodchild, Conjugates of Oligonucleotides and Modified Oligonucleotides: a Review oftheir Synthesis and properties, Vol. 1, No. 3, 1990, pp.
- oligonucleotides can be obtained according to the conventional methods known to those skilled in the art, and it is also possible to synthesize oligonucleotides modified according to the methods described in Bioconjugate Chemistry, John Goodchild, Conjugates of Oligonucleotides and Modified Oligonucleotides: a Review of their Synthesis and properties, Vol. 1, No. 3, 1990, pp. 165-187 or in Tetrahedron, Beaucage et al., 772nd Synthesis of Modified ⁇ Oligonucleotides by the Phosphoramiditeb Approach and Their Application, Vol. 49, No. 28, pp. 6123-6194, 1993.
- peptide is intended to mean chains containing one or more amino acids linked together by bonds of peptide nature [Lehninger Biochimie, Flammarion Médecine Sciences, 2nd edition]. These can be the 20 "classic” amino acids, that is to say those commonly found in the composition of proteins (Alamine, Valine, Leucine, Isoleucine, Proline, Phenylalamine, Tryptophan, Methionine, Aspartic Acid, Glutamine, Lysine, Arginine, Histidine, Glycine, Serine, Threonine, Cysteine, Tyrosine, Asparagine, Glutamic Acid), or it can also be the so-called "rare” amino acids such as 4-hydroxyproline, desmosine, 5 -hydroxylysine, N-methyllysine, 3-methylhistidine, episodesmosine etc.
- amino acids appearing in different cells or various tissues in free or combined form may also be the amino acids appearing in different cells or various tissues in free or combined form and which generally derive from ⁇ acids -aminated (for example ⁇ -alamine, ⁇ -aminobutyric acid, homocysteine, ornithine, canavanine, djenkalic acid, ⁇ -cyanoalamine etc.).
- ⁇ acids -aminated for example ⁇ -alamine, ⁇ -aminobutyric acid, homocysteine, ornithine, canavanine, djenkalic acid, ⁇ -cyanoalamine etc.
- Such peptides can for example allow targeting of certain cell types.
- linear or cyclic peptide or pseudopeptide sequences comprising the Arg-Gly-Asp epitope (Arginine-Glycine-Aspartic Acid) for recognition of the primary and / or secondary receptors for adhesion proteins of the integrin type.
- the peptides according to the invention can also be substituted at the level of one or more of their functional groups, for example at the level of the ⁇ carboxyl, of the amino function in ⁇ and / or at the level of the functional groups of the side chain of each of the amino acids.
- substitutions with saturated or unsaturated, linear, branched or cyclic aliphatic groups containing 1 to 24 carbon atoms such as for example cholesteryl, arachidonyl or retinoyl radicals, or alternatively mono- or polyaromatics such as, for example, substituted or unsubstituted benzyloxycarbonyl, benzylester or rhodaminyl derivatives.
- cholesteryl arachidonyl or retinoyl radicals
- mono- or polyaromatics such as, for example, substituted or unsubstituted benzyloxycarbonyl, benzylester or rhodaminyl derivatives.
- hydrophilic substituent these are chosen from hydrophilic peptides, that is to say peptides consisting only of hydrophilic amino acids or those partially composed of hydrophilic amino acids and the composition makes them generally hydrophilic.
- the Z groups all represent hydrogen atoms.
- the transfer agents have the general formula (III):
- x and y independently of one another, represent integers between 10 and 22 inclusive
- X and Y independently of each other, represent a hydrogen atom or a sugar, being it being understood that at least one of the substituents X and Y represents a sugar, - either x is equal to 0 or 1, y is an integer between 20 and 50, X is a hydrogen atom and Y is a sugar.
- the polycation, the sugars and x and y in the general formula (III) are as defined above for the general formula (I).
- More particularly preferred transfer agents are of general formula (III) and x and y, independently of one another, represent integers between 10 and 22 inclusive, and one of X and Y represents an atom d hydrogen and the other a sugar.
- the transfer agents according to the invention have the general formula (III) and x is equal to 0, y is an integer between 40 and 50, X represents a hydrogen atom, and Y is a sugar.
- the present invention also relates to the isomers of the products of general formula (I) when they exist, as well as their mixtures, or their salts.
- the compounds of the invention can be in the form of non-toxic and pharmaceutically acceptable salts.
- non-toxic salts include the salts with mineral acids (for example hydrochloric, sulfuric, hydrobromic, phosphoric, nitric), with organic acids (acetic, propionic, succinic, maleic, hydroxymaleic, benzoic, fumaric, methanesulfonic or oxalic), with mineral bases (soda, potash, lithine, lime), or with organic bases (tertiary amines such as triethylamine, piperidine, benzylamine).
- mineral acids for example hydrochloric, sulfuric, hydrobromic, phosphoric, nitric
- organic acids acetic, propionic, succinic, maleic, hydroxymaleic, benzoic, fumaric, methanesulfonic or oxalic
- mineral bases for example hydrochloric, sulfuric, hydrobromic, phosphoric, nitric
- organic acids
- An alkyl chain containing x carbon atoms (x being defined as above), comprising a hydroxy function and an ester function, is firstly prepared by opening a corresponding lactone.
- the reaction is generally carried out in an alcohol, at basic pH and at a temperature between -10 ° C and room temperature.
- the alcohol can be methanol or ethanol.
- group X is fixed to the bifunctional alkyl chain obtained in the previous step.
- X represents a sugar
- condensation is carried out in a chlorinated solvent, such as, for example, dichloromethane or chloroform, and in the presence of a Lewis acid, at a temperature between -5 ° C. and 10 ° C.
- Lewis acid can for example be chosen from tin chloride, iron chloride, p-toluene sulfonic acid (tsOH), trimethylsillyltrifluoromethane sulfonic (TMStf), boron trifluoride etherate etc. [Kazunobu Toshima et al., Recent Progress in O-glcosilation Methods and its Application to Natural Products Synthesis, Chem. Rev. 1993, Vol. 93, pp. 1503-1531].
- X represents a hydrophilic peptide group or not
- peptide coupling is carried out according to conventional methods (Bodanski M., Principles and Practices of Peptides Synthesis, Ed.
- the reaction is generally carried out in the presence of a non-nucleophilic base in suitable aprotic solvents, at a temperature between 0 and 100 ° C., the pH being adjusted between 9 and 1 1.
- a non-nucleophilic base in suitable aprotic solvents, at a temperature between 0 and 100 ° C., the pH being adjusted between 9 and 1 1.
- the chloroform, dimethylformamide, methylpyrrolidone, acetonitrile, dichloromethane, toluene or benzene can be used as a solvent.
- the non-nucleophilic bases used are preferably tertiary amines, calcium carbonate or sodium dicarbonate.
- the bases used are tertiary amines such as, for example, triethylamine (TEA) or N-ethyldiisopropylamine.
- TAA triethylamine
- N-ethyldiisopropylamine a tertiary amine
- the peptide coupling is carried out between 0 and 50 ° C, and preferably between 10 and 30 ° C.
- X represents an —OAlk group
- the alcohol function is alkylated according to the conventional methods known to a person skilled in the art or by analogous methods.
- a diazo compound of formula can be reacted general Alk-N 2 optionally in the presence of a catalyst such as HBF 4 or silica gel.
- a catalyst such as HBF 4 or silica gel.
- We can also operate under the conditions of the Williamson Reaction which consists in reacting in basic medium a compound of general formula Alk-Hal where Hal represents a halogen atom such as chlorine, bromine or iodine, on the chain carrying an alcohol function.
- X represents an oligonucleotide
- it is coupled to the bifunctional chain according to the conventional methods known for covalently grafting an oligonucleotide.
- said oligonucleotide can be grafted via a suitable linker.
- ester function present on the bifunctional chain is hydrolyzed to an acid function according to known methods. For example, one can operate in a basic medium in an alcohol with a high boiling point, at a temperature between 50 ° C. and the reflux temperature of the reaction mixture.
- the reaction is generally carried out in the presence of a non-nucleophilic base in suitable aprotic solvents, at a temperature between 0 and 100 ° C., the pH being adjusted between 9 and 11.
- a non-nucleophilic base in suitable aprotic solvents, at a temperature between 0 and 100 ° C., the pH being adjusted between 9 and 11.
- a non-nucleophilic base in suitable aprotic solvents, at a temperature between 0 and 100 ° C.
- suitable aprotic solvents for example, chloroform , dimethylformamide, methylpyrrolidone, acetonitrile, dichloromethane, toluene or benzene can be used as solvent.
- the non-nucleophilic bases used are preferably tertiary amines, carbonate of calcium or sodium dicarbonate. Even more preferably, the bases used are tertiary amines such as, for example, triethylamine (TEA)
- the peptide coupling is carried out between 0 and 50 ° C, and preferably between 10 and 30 ° C.
- the group of general formula (IV) is either commercially available or it can be obtained by condensation of Y on the corresponding unsubstituted alkylamine according to a method analogous to that described previously in 2).
- the amide obtained in the previous step is then reduced to an amine.
- This is done according to conventional methods known to those skilled in the art.
- an anhydrous organic solvent such as anhydrous tetrahydrofuran
- LiAlH 4 lithium aluminum hydride
- Other reducing agents which can be used are for example borane, borane in dimethylsulfide (BH 3 - SMe 2 ), sodium borohydride / titanium tetrachloride (NaBH 4 , TiCl 4 ), phosphorus oxide chloride on Zinc (POCl 3 / Zn), phosphorus pentasulfide (P 4 S 10 ) on Raney nickel, etc.
- borane borane in dimethylsulfide
- NaBH 4 , TiCl 4 sodium borohydride / titanium tetrachloride
- P 4 S 10 phosphorus pentasulfide
- the acid derivative corresponding to polycation R as defined above is coupled to the compound of general formula (IV) obtained in the previous step, according to conventional peptide coupling methods (Bodanski M., Principles and Practices of Peptides Synthesis, Ed. Springe-Verlag) or by any analogous method known to those skilled in the art.
- the reaction is generally carried out in the presence of a non-nucleophilic base in suitable aprotic solvents, at a temperature between 0 and 100 ° C., the pH being adjusted between 9 and 11.
- the non-nucleophilic bases used are preferably tertiary amines, calcium carbonate or sodium dicarbonate. Even more preferably, the bases used are tertiary amines such as, for example, triethylamine (TEA) or N-ethyldiisopropylamine.
- TAA triethylamine
- N-ethyldiisopropylamine the peptide coupling is carried out between 0 and 50 ° C, and preferably between 10 and 30 ° C.
- the acid derivatives corresponding to the polycation are commercially available.
- the transfecting agents according to the present invention can be prepared by operating as follows:
- An alkyl chain containing x carbon atoms (x being defined as above), comprising a hydroxy function and an ester function, is firstly prepared by opening a corresponding lactone.
- the reaction is generally carried out in an alcohol, at basic pH and at a temperature between -10 ° C and room temperature.
- the alcohol can be methanol or ethanol.
- the reaction is carried out at a temperature above the melting point of each product, with or without vacuum.
- the reaction can also be carried out at reflux temperature in the presence of an alcoholic solvent.
- the solvent can be methanol or ethanol.
- reaction can also be carried out at reflux temperature of the mixture in the presence of an alcohol such as methanol as solvent.
- Another alternative consists in coupling the compound of general formula (IV) directly with the lactone (in this case, the first step of opening the lactone is not carried out).
- the group of general formula (IV) is either commercially available or it can be obtained by condensation of Y on the corresponding unsubstituted alkylamine according to a method analogous to that described above.
- the acid derivative corresponding to polycation R as defined above is coupled to the compound of general formula (VI) obtained in the previous step, according to conventional peptide coupling methods (Bodanski M., Principles and Practices of Peptides Synthesis, Ed. Springe-Verlag) or by any analogous method known to those skilled in the art.
- the reaction is generally carried out in the presence of a non-nucleophilic base in suitable aprotic solvents, at a temperature between 0 and 100 ° C., the pH being adjusted between 9 and 11.
- chloroform dimethylformamide, methylpyrrolidone, acetonitrile, dichloromethane, toluene or benzene can be used as solvent.
- the non-nucleophilic bases used are preferably tertiary amines, calcium carbonate or sodium dicarbonate. Even more preferably, the bases used are tertiary amines such as, for example, triethylamine (TEA) or N-ethyldiisopropylamine.
- TAA triethylamine
- N-ethyldiisopropylamine tertiary amines
- the peptide coupling is carried out between 0 and 50 ° C, and preferably between 10 and 30 ° C.
- the acid derivatives corresponding to the polycation are commercially available.
- nucleic acid transfer agents As an illustrative example of advantageous nucleic acid transfer agents according to the invention, mention may be made of the following compounds:
- compositions comprising a nucleic acid transfer agent as defined above, and a nucleic acid.
- the respective amounts of each component can be easily adjusted by those skilled in the art depending on the transfer agent used, the nucleic acid, and the desired applications (in particular the type of cells to be transfected).
- nucleic acid is understood to mean both a deoxyribonucleic acid and a ribonucleic acid. They may be natural or artificial sequences, and in particular genomic DNA (gDNA), complementary DNA
- CDNA messenger RNA
- mRNA messenger RNA
- tRNA transfer RNA
- RRNA hybrid sequences or synthetic or semi-synthetic sequences, modified or unmodified oligonucleotides.
- These nucleic acids can be of human, animal, plant, bacterial, viral, etc. origin. They can be obtained by any technique known to those skilled in the art, and in particular by screening of banks, by chemical synthesis, or also by mixed methods including chemical or enzymatic modification of sequences obtained by screening of libraries. They can be chemically modified.
- deoxyribonucleic acids can be single or double stranded as well as short oligonuleotides or longer sequences.
- the nucleic acids advantageously consist of plasmids, vectors, episomes, expression cassettes, etc.
- deoxyribonucleic acids can carry an origin of functional or non-functional replication in the target cell, one or more marker genes, transcription or replication regulatory sequences, genes of therapeutic interest, modified or unmodified antisense sequences, regions to other cellular components, etc.
- the nucleic acid comprises one or more genes of therapeutic interest under the control of regulatory sequences, for example one or more promoters and a transcriptional terminator active in the target cells.
- regulatory sequences for example one or more promoters and a transcriptional terminator active in the target cells.
- the term “gene of therapeutic interest” is understood to mean any gene coding for a protein product having a therapeutic effect.
- the protein product thus coded can in particular be a protein or a peptide.
- This protein product can be exogenous homologous or endogenous with respect to the target cell, that is to say a product which is normally expressed in the target cell when the latter presents no pathology.
- the expression of a protein makes it possible for example to compensate for an insufficient expression in the cell or the expression of an inactive or weakly active protein due to a modification, or else to overexpress said protein.
- the gene of therapeutic interest can also code for a mutant of a cellular protein, having increased stability, activity modified, etc.
- the protein product can also be heterologous towards the target cell.
- an expressed protein can, for example, supplement or bring about a deficient activity in the cell, allowing it to fight against a pathology, or stimulate an immune response.
- therapeutic products within the meaning of the present invention, there may be mentioned more particularly enzymes, blood derivatives, hormones, lymphokines: interleukins, interferons, TNF, etc. (FR 92/03120), growth factors, neurotransmitters or their precursors or synthetic enzymes, trophic factors (BDNF, CNTF, NGF, IGF, GMF, aFGF, bFGF, NT3, NT5, HARP / pleiotrophin, etc.
- BDNF trophic factors
- CNTF NGF
- IGF IGF
- GMF aFGF
- bFGF thelial growth factor
- NT3, NT5 HARP / pleiotrophin
- apolipoproteins (ApoAI, ApoAIV, ApoE, etc., FR 93/05125), dystrophin or a minidystrophin (FR 91/1 1947), the CFTR protein associated with cystic fibrosis, tumor suppressor genes (p53, Rb, RaplA, DCC, k-rev, etc., FR 93/04745), genes coding for factors involved in coagulation (Factors VII, VIII, IX), genes involved in DNA repair, suicide genes (thymidine kinase, cytosine deaminase), genes of hemoglobin or other protein transporters, enzymes of metabolism, catabolism etc.
- the nucleic acid of therapeutic interest can also be an antisense gene or sequence, the expression of which in the target cell makes it possible to control the expression of genes or the transcription of cellular mRNAs.
- Such sequences can, for example, be transcribed in the target cell into RNAs complementary to cellular mRNAs and thus block their translation into protein, according to the technique described in patent EP 140 308.
- the therapeutic genes also include the sequences coding for ribozymes, which are capable of selectively destroying target RNAs (EP 321,201).
- the nucleic acid can also contain one or more genes coding for an antigenic peptide, capable of generating in humans or animals an immune response.
- the invention makes it possible to carry out either vaccines or immunotherapeutic treatments applied to humans or animals, in particular against microorganisms, viruses or cancers.
- These may in particular be antigenic peptides specific for the Epstein Barr virus, the HIV virus, the hepatitis B virus (EP 185 573), the pseudo-rabies virus, the "syncitia forming virus", d other viruses or tumor-specific antigenic peptides (EP 259,212).
- the nucleic acid also comprises sequences allowing the expression of the gene of therapeutic interest and / or of the gene coding for the antigenic peptide in the desired cell or organ.
- sequences which are naturally responsible for the expression of the gene considered when these sequences are capable of functioning in the infected cell. It can also be sequences of different origin (responsible for the expression of other proteins, or even synthetic).
- they may be promoter sequences of eukaryotic or viral genes.
- they may be promoter sequences originating from the genome of the cell which it is desired to infect.
- they may be promoter sequences originating from the genome of a virus.
- promoters of the E1A, MLP, CMV, RSV, etc. genes can be modified by adding activation, regulation sequences, etc. It can also be a promoter, inducible or repressible.
- the nucleic acid can also comprise, in particular upstream of the gene of therapeutic interest, a signal sequence directing the therapeutic product synthesized in the secretory pathways of the target cell.
- This signal sequence may be the natural signal sequence of the therapeutic product, but it may also be any other functional signal sequence, or an artificial signal sequence.
- the nucleic acid may also include a signal sequence directing the synthesized therapeutic product to a particular compartment of the cell.
- the compositions according to the invention may also comprise one or more adjuvants capable of associating with the transfer agent / nucleic acid complexes and of improving their transfecting power.
- the present invention therefore relates to compositions comprising a nucleic acid, a nucleic acid transfer agent as defined above and at least one adjuvant capable of associating with the transfer agent complexes / nucleic acid and improve its transfecting power.
- a nucleic acid transfer agent as defined above
- at least one adjuvant capable of associating with the transfer agent complexes / nucleic acid and improve its transfecting power.
- the presence of this type of adjuvant lipids, peptides or proteins for example
- the compositions of the invention can comprise, as an adjuvant, one or more neutral lipids.
- the neutral lipids used in the context of the present invention are lipids with two fatty chains.
- natural or synthetic lipids are used, zwitterionic or devoid of ionic charge under physiological conditions. They can be chosen more particularly from dioleoylphosphatidylethanolamine (DOPE), oleoylpalmitoylphosphatidylethanolamine (POPE), distearoyl, - palmitoyl, -mirystoylphosphatidylethanolamines as well as their N-methylated derivatives, phosphatidyl glycols, cerebrosides (such as in particular galactocerebrosides), sphingolipids (such as in particular sphingomyelines) or also asialogangliosides (such as in particular asialoGMl and GM2).
- DOPE dioleoylphosphatidylethanolamine
- POPE oleoylpalmitoylphosphatidylethanolamine
- lipids can be obtained either by synthesis or by extraction from organs (example: the brain) or eggs, by conventional techniques well known to those skilled in the art.
- extraction of natural lipids can be carried out using organic solvents (see also
- a compound intervening or not directly at the level of the condensation of said nucleic acid such as those described in patent application WO 96/25508.
- the presence of such a compound, within a composition according to the invention, makes it possible to reduce the amount of transfecting agent, with the beneficial consequences which result therefrom from the toxicological point of view, without causing any damage to the activity. transfectant.
- compound involved in the condensation of nucleic acid is meant to define a compacting compound, directly or indirectly, nucleic acid.
- this compound can either act directly at the level of the nucleic acid to be transfected or intervene at the level of an annex compound which is directly involved in the condensation of this nucleic acid.
- the precompacting agent can be any polycation, for example polylysine.
- the agent involved in the condensation of the nucleic acid derives in whole or in part from a protamine, a histone, or a nucleoline and / or one of their derivatives.
- Such an agent can also consist, in whole or in part, of peptide units (KTPKKAKKP) and / or (ATPAKKAA), the number of units can vary between 2 and 10.
- these units can be repeated continuously or not. Thus they can be separated by links of a biochemical nature, for example by one or more amino acids, or of a chemical nature.
- compositions of the invention comprise from 0.01 to 20 equivalents of adjuvant for one equivalent of nucleic acid in mol / mol and, more preferably, from 0.5 to 5.
- compositions according to the present invention further comprise a targeting element making it possible to direct the transfer of the nucleic acid.
- This targeting element can be an extracellular targeting element making it possible to direct the transfer of DNA to certain, cell types or certain desired tissues (tumor cells, hepatic cells, hematopoietic cells, etc.). It can also be a targeting element intracellular allowing to direct the transfer of the nucleic acid towards certain privileged cellular compartments (mitochondria, nucleus etc.).
- the targeting element can be linked to the nucleic acid transfer agent according to the invention, or also to the nucleic acid as has been specified above. When the targeting element is linked to the nucleic acid transfer agent of general formula (I), the latter preferably constitutes one of the substituents X or Y.
- sugars, peptides, proteins, oligonucleotides, lipids, neuromediators, hormones, vitamins or their derivatives there may be mentioned sugars, peptides or proteins such as antibodies or antibody fragments, ligands of cellular receptors or fragments thereof, receptors or fragments of receptors, etc.
- they may be ligands for growth factor receptors, cytokine receptors, cell lectin receptors, or ligands with RGD sequence with an affinity for adhesion protein receptors such as integrins. Mention may also be made of the transferrin, HDL and LDL receptors, or the folate transporter.
- the targeting element can also be a sugar making it possible to target lectins such as receptors for asialoglycoproteins or for syalydes such as sialyl Lewis X, or alternatively an Fab fragment of antibodies, or a single chain antibody (ScFv).
- lectins such as receptors for asialoglycoproteins or for syalydes such as sialyl Lewis X, or alternatively an Fab fragment of antibodies, or a single chain antibody (ScFv).
- the association of the targeting elements with the nucleolipid complexes can be carried out by any technique known to those skilled in the art, for example by coupling to a hydrophobic part or to a part which interacts with the nucleic acid of the transfer agent according to the invention, or to a group which interacts with the transfer agent according to the invention or with the nucleic acid.
- the interactions in question can be, according to a preferred mode, of ionic or covalent nature.
- a subject of the invention is also the use of the compounds as defined above for the transfer of polynucleotides (and more generally of polyanions) in cells in vitro, in vivo or ex vivo. More specifically, the subject of the present invention is the use of the compounds as defined above for the preparation of a medicament intended for treating diseases, in particular diseases which result from a deficiency in a protein or nucleic product.
- the polynucleotide contained in said drug encodes said protein or nucleic product, or constitutes said nucleic product, capable of correcting said diseases in vivo or ex vivo.
- compositions according to the invention can be formulated for topical, cutaneous, oral administration. , rectal, vaginal, parenteral, intranasal, intravenous, intramuscular, subcutaneous, intraocular, transdermal, intratracheal, intraperitoneal, etc.
- the compositions of the invention contain a pharmaceutically acceptable vehicle for an injectable formulation, in particular for a direct injection into the desired organ, or for topical administration (on the skin and / or mucosa).
- nucleic acids used for the injection may in particular be sterile, isotonic solutions, or dry compositions, in particular lyophilized, which, by addition as appropriate of sterilized water or physiological saline, allow the constitution of injectable solutes.
- the doses of nucleic acids used for the injection as well as the number of administrations can be adapted as a function of various parameters, and in particular as a function of the mode of administration used, of the pathology concerned, of the gene to be expressed, or else the duration of the treatment sought.
- the mode of administration it may be either a direct injection into the tissues, for example at the level of tumors, or into the circulatory tract, or a treatment of cultured cells followed of their reimplantation in vivo, by injection or graft.
- the tissues concerned in the context of the present invention are for example the muscles, the skin, the brain, the lungs, the liver, the spleen, the bone marrow, the thymus, the heart, the lymph, the blood, the bones, cartilage, pancreas, kidneys, bladder, stomach, intestines, testes, ovaries, rectum, nervous system, eyes, glands, connective tissue, etc.
- Another object of the present invention relates to a method of treatment of the human or animal body comprising the following steps: (1) bringing the nucleic acid into contact with a transfer agent as defined above, to form a complex , and
- the invention further relates to a method for transferring nucleic acids into cells, comprising the following steps:
- the contacting of the cells with the complex can be carried out by incubation of the cells with the said complex (for uses in vitro or ex vivo), or by injection of the complex into an organism (for uses in vivo).
- the incubation is preferably carried out in the presence of, for example, from 0.01 to 1000 ⁇ g of nucleic acid per 10 6 cells.
- doses of nucleic acid ranging from 0.01 to 10 mg can for example be used.
- compositions of the invention additionally contain one or more adjuvants as defined above
- the adjuvant (s) are mixed beforehand with the transfer agent according to the invention and / or with the nucleic acid.
- the present invention thus provides a particularly advantageous method for the transfer of nucleic acids in vivo, in particular for the treatment of diseases, comprising the administration in vivo or in vitro of a nucleic acid coding for a protein or capable of being transcribed into a nucleic acid able to correct said disease, said nucleic acid being associated with a compound of general formula (I) under the conditions defined above.
- the nucleic acid transfer agents of the invention are particularly useful for the transfer of nucleic acids into primary cells or into established lines. They can be fibroblastic, muscular, nervous cells (neurons, astrocytes, glial cells), hepatic, hematopoietic (lymphocytes, CD34, dendritics, etc.), epithelial etc., in differentiated or pluripotent forms (precursors).
- the present invention also includes other characteristics and advantages which will emerge from the examples and figures which follow, and which should be considered as illustrating the invention without limiting its scope.
- the applicant proposes, without limitation, various operating protocols as well as reaction intermediates which may be used to prepare the transfer agents of general formula (I).
- various operating protocols as well as reaction intermediates which may be used to prepare the transfer agents of general formula (I).
- It is also for those skilled in the art to draw inspiration from the synthesis methods described in the various patent applications cited above for the synthesis of polycation R included in the general formula (I) (WO 96/17823, WO 97/18185 , WO 97/31935 etc.).
- Figure 1 Schematic representation of the plasmid pXL2774 used in DNA transfer experiments in cells.
- Figure 2 In vitro gene transfer activity in HeLa cells of the complexes formed from compound 2 according to the invention without co-lipid, or else in the presence of cholesterol and in the presence of DOPE as co-lipids.
- the y-axis represents the expression of luciferase in pg / well.
- the absentee axis indicates the transfecting agent / DNA ratio in nmol / ⁇ g of DNA.
- Figure 3 In vivo gene transfer activity after direct injection into the anterior muscle of the mouse tibia of complexes formed from compound 2 according to the present invention in the presence of DOPE (1: 1).
- the ordinate axis indicates the expression of luciferase in pg / muscle.
- the absentee axis indicates the compound 2 / DNA ratio in nmoles / ⁇ g of DNA.
- the starting polyamines such as spermidine, spermine, tris- (2-aminoethyl) amine, phenylenediamine, diaminoalkane etc.
- the starting polyamines are commercially available or they can be synthesized by conventional methods (for example by cyanoethylation of commercially available amines to obtain branched amines)
- Amberlite IR 120 is a commercial ion exchange resin (BDH catalog). • Dimethyl sulfoxide (DMSO), treated beforehand with potassium hydroxide, was distilled over calcium hydride and then stored on a 4 A molecular sieve.
- DMSO Dimethyl sulfoxide
- Tetrahydrofuran (THF) was distilled over sodium in the presence of benzophenone. • For reactions requiring anhydrous conditions, all glassware is flame dried under a stream of nitrogen.
- the nuclear magnetic resonance (NMR) spectra were recorded on a Brucker MSL 30 spectrometer at the frequency of 300 MHz for the proton and 75 MHz for the carbon. All chemical shifts are reported in ppm either relative to the frequency of tetramethylsilane (TMS), or relative to the solvent. The spectra were recorded using either the TMS or the residual solvent signal as an internal reference.
- the multiplicity of signals is designated by the following abbreviations: s (singlet), d (doublet), t (triplet), q (quadruplet) and m (multiplet).
- HPLC analyzes High Performance Liquid Chromatography
- a Waters LC 4000 device equipped with a C4 type analytical column marketed by Applied Biosystem ("Brownlee Columns” in stainless steel 3 cm long and 0.46 cm diameter) and a "Waters 486" detector at 220 nm.
- the stationary phase is 7 microns butyl aquapore, and the mobile phases are demineralized water (2500 cm 3 ) or acetonitrile (2500 cm 3 ) added with trifluoroacetic acid (2.5 cm 3 ).
- the flow rate is 1 ml per minute.
- Methyl 1-ol-pentadecanoate is obtained with a yield of 80%.
- step c) 5.08 g of product obtained in step c) (9.34 mmol) in solution in 20 cm 3 of methanol are treated with 9.34 ml of 2N sodium methylate (18.68 mmol). When the reaction is complete, the reaction mixture is neutralized with Amberlite IR120, filtered and evaporated to dryness under vacuum.
- H-6 1.27 (m, 14H, (CH 2 ) 25), 1.4-1.6 (m, 17H, OCH 2 ⁇ H 2 , H-17, H-14, H-17, H -37, H-40, H-41 and H-44), l, 46 (m, 36H, Boc), 2.8-2.9 (m, 6H, H-15, H-16 and H-35 ), 3.09-
- step i) To a solution of the product obtained in previous step i) (0.072 g; 0.05 mmol), 10% palladium on carbon (0.032 g) is added in methanol. After one night, filter on glass paper and concentrate on a rotary evaporator. The product is then purified by HPLC on a preparative column of type C-4.
- This example illustrates the preparation of complexes between a transfer agent according to the invention and a nucleic acid, their size having then been measured.
- glycolipid used in this example and in the examples which follow is compound 2, in solution in chloroform, at a concentration of 10 mg / ml. In in some cases, a neutral co-lipid, cholesterol or DOPE, was previously mixed with compound 2.
- the lipid solution is prepared as follows: a sample of the desired quantity is taken, the solvent is evaporated under a stream of argon and allowed to dry for 1 hour. Then, the lipid is rehydrated with a solution containing 5% dextrose and 10 mM sodium chloride overnight at 4 ° C. The next day, the lipid solutions are heated at 60 ° C for 5 minutes and then passed through ultrasound for 1 minute. The operation is repeated until the size of the lipid particles is stable.
- the DNA used is the plasmid pXL3031 (FIG. 1) in solution in a mixture of 5% dextrose and 10 mM sodium chloride at a concentration of 0.5 mg / ml or 1.0 mg / ml.
- This plasmid contains the read gene coding for luciferase under the control of the P / E CMV promoter of the cytomegalovirus. Its size is 3671 bp.
- the diagram of this plasmid is shown in FIG. 1.
- the plasmid pXL3031 was purified according to the methods described in patent application WO 97/35002.
- the compound 2 / DNA complexes are prepared by rapidly mixing appropriate volumes of plasmid DNA solution and of compound 2 (according to the desired charge ratio), at room temperature.
- the amount of transfecting agent varies between 0.25 nmol / ⁇ g of DNA and 12 nmol / ⁇ g of DNA.
- the size of the complexes was analyzed by measuring the hydrodynamic diameter by dynamic light scattering (Dynamic Laser Light Scattering) using a Coulter N4Plus device.
- the samples are diluted 20 times in a solution containing 5% dextrose and 20 mM sodium chloride to avoid multiple diffusions.
- a ratio of 3 nmoles of lipid / ⁇ g of DNA the following results were obtained:
- micellar solution indicates that compound 2 was used alone, that is to say without adding neutral co-lipid, and therefore it forms a micellar solution.
- This table shows that the complexes obtained have a size of between 130 nm and 150 nm approximately, which is compatible with pharmaceutical use, in particular in injection.
- Example 5 Behavior of the complexes formed from compound 2 at different charge ratios
- This example illustrates the behavior of the transfer agent complexes according to the invention / nucleic acid when the charge ratio is varied.
- the impact of adding a co-lipid is also illustrated.
- phase A the DNA is not saturated with the transfer agent. Uncomplexed DNA remains, and the complexes are generally negatively charged and small. This stable phase is called "Phase A".
- the fact that the DNA is not completely saturated with the transfer agent means that the DNA is not completely protected. DNA can therefore be subjected to degradation by nucleases. Furthermore, the complexes being generally negative, the passage of the cell membrane is difficult. For these reasons, the nucleolipid complexes of phase A are relatively inactive.
- phase B Such a complex size is not suitable for use in injection, although this does not mean that the complexes are inactive in phase B: they are only in a formulation which is not suitable for their injection for a purpose. pharmaceutical.
- phase C the complexes obtained are in a form such that DNA is very well protected against nucleases, and the generally positive charge of these complexes facilitates attachment to the cell membrane of an anionic nature and the passage of this membrane.
- the complexes of phase C are therefore particularly suitable for use for the transfer of nucleic acids into cells.
- zone B which is the zone of instability, is particularly small and is located at very low load ratios.
- Zone C starts from 2 nmoles of lipid / ⁇ g of DNA when compound 2 is used in conjunction with a co-lipid (Cholesterol or DOPE), and from 3 nmoles of lipid / ⁇ g of DNA when the compound is used alone.
- a co-lipid Cholesterol or DOPE
- zone C began to form at charge ratios at least equal to 2 depending on the concentration of sodium chloride in the solution (see Figure 3 A in B. Pitard et al., PNAS USA, 94, pp. 14412-14417, 1997).
- compound 2 is a particularly advantageous transfer agent because it is stable at low charge ratios, which makes it possible to form stable complexes with low amounts of glycolipids, with the beneficial consequences which ensue in terms of toxicity.
- Example 6 Use of Compound 2 for the In Vitro Transfer of DNA This example illustrates the capacity of the transfer agents according to the invention to transfect DNA in cells in vitro, at different charge ratios, in the absence and in the presence of a neutral co-lipid (cholesterol or DOPE).
- cholesterol cholesterol or DOPE
- 24-well microplates are seeded with 60,000 HeLa cells per well, and are grown overnight. The number of cells after one night, and therefore at the time of transfection, is 100,000 cells per well.
- Each well is brought into contact with the complexes formed with compound 2 and containing 1 ⁇ g of plasmid DNA in 0.5 ml of DMEM culture medium (Gibco / BRL without serum.
- the cells are incubated at 37 ° C. for 5
- the medium containing the complexes is then removed and replaced with a DMEM culture medium and 10% fetal calf serum.
- the cells are again cultured for 24 hours.
- the cells are lysed and tested in using a luciferase test kit (Promega) and a Dynex MLX luminometer.
- Example 7 Use of Compound 2 for the In Vivo Transfer of DNA This example illustrates the capacity of the transfer agents according to the invention to transfect DNA in cells in vivo.
- each mouse received 30 ⁇ l of formulation containing 15 ⁇ g of plasmid DNA in the anterior tibia muscle.
- the tissues are recovered 7 days after the injection, they are frozen and stored at -80 ° C while waiting to carry out the luciferase activity tests.
- each mouse received 200 ⁇ l of formulation containing 50 ⁇ g of plasmid DNA.
- the tissues are recovered 24 hours after the injection, then are frozen and stored in the same way as above.
- FIG. 3 illustrates the activity of the complexes formed with compound 2 for gene transfer in vivo intramuscularly.
- any transfer agent as defined in the present invention can be used to promote the transfer of DNA into cells of any type of tissue.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99958234A EP1137793A2 (fr) | 1998-12-03 | 1999-12-02 | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations |
BR9915897-3A BR9915897A (pt) | 1998-12-03 | 1999-12-02 | Agentes de transferência de ácidos nucleicos, composição, utilização de um agente de transferência e processos de tratamento de corpo humano ou animal e de transferência de ácidos nucleicos. |
KR1020017006897A KR20010101116A (ko) | 1998-12-03 | 1999-12-02 | 신규 핵산 전달제, 이를 함유하는 조성물 및 용도 |
IL14270499A IL142704A0 (en) | 1998-12-03 | 1999-12-02 | Novel nucleic acid transferring agents, compositions containing them and uses |
JP2000585434A JP2002531468A (ja) | 1998-12-03 | 1999-12-02 | 新規核酸導入剤、前記核酸導入剤を含有する組成物及びその使用 |
CA002353576A CA2353576A1 (fr) | 1998-12-03 | 1999-12-02 | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations |
AU15646/00A AU772033B2 (en) | 1998-12-03 | 1999-12-02 | Novel nucleic acid transferring agents, compositions containing them and uses |
PL99348513A PL348513A1 (en) | 1998-12-03 | 1999-12-02 | Novel nucleic acid transferring agents, compositions containing them and uses |
NO20012684A NO20012684L (no) | 1998-12-03 | 2001-05-31 | Nye nukleinsyreoverföringsmidler, med preparater inneholdende disse, samt deres anvendelse |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR98/15309 | 1998-12-03 | ||
FR9815309A FR2786700B1 (fr) | 1998-12-03 | 1998-12-03 | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations |
US11718499P | 1999-01-26 | 1999-01-26 | |
US60/117,184 | 1999-01-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000032803A2 true WO2000032803A2 (fr) | 2000-06-08 |
WO2000032803A3 WO2000032803A3 (fr) | 2000-10-12 |
Family
ID=26234691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/002995 WO2000032803A2 (fr) | 1998-12-03 | 1999-12-02 | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1137793A2 (fr) |
JP (1) | JP2002531468A (fr) |
KR (1) | KR20010101116A (fr) |
CN (1) | CN1348498A (fr) |
AU (1) | AU772033B2 (fr) |
BR (1) | BR9915897A (fr) |
CA (1) | CA2353576A1 (fr) |
CZ (1) | CZ20011909A3 (fr) |
HU (1) | HUP0200345A3 (fr) |
IL (1) | IL142704A0 (fr) |
NO (1) | NO20012684L (fr) |
PL (1) | PL348513A1 (fr) |
WO (1) | WO2000032803A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2805271B1 (fr) * | 2000-02-18 | 2002-04-26 | Aventis Pharma Sa | Procede de preparation de polyalkylenimines fonctionnalises, compositions les contenant et leurs utilisations |
JP2005080598A (ja) * | 2003-09-10 | 2005-03-31 | Japan Science & Technology Agency | β−1,3−グルカン誘導体を用いるプラスミドDNAの導入法 |
CN103820320B (zh) * | 2013-06-25 | 2017-03-15 | 宁波有成生物医药科技有限公司 | 一种非冻型rna保护液 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996021036A2 (fr) * | 1994-12-30 | 1996-07-11 | Chiron Viagene, Inc. | Agents de concentration d'acide nucleique ayant une immunogenicite reduite |
WO1996025508A1 (fr) * | 1995-02-17 | 1996-08-22 | Rhone-Poulenc Rorer S.A. | Compositions contenant des acides nucleiques, preparation et utilisation |
WO1998006869A1 (fr) * | 1996-08-14 | 1998-02-19 | The Children's Hospital Of Philadelphia | Vehicules non viraux a utiliser dans le transfert genique |
-
1999
- 1999-12-02 IL IL14270499A patent/IL142704A0/xx unknown
- 1999-12-02 CA CA002353576A patent/CA2353576A1/fr not_active Abandoned
- 1999-12-02 PL PL99348513A patent/PL348513A1/xx not_active Application Discontinuation
- 1999-12-02 JP JP2000585434A patent/JP2002531468A/ja not_active Withdrawn
- 1999-12-02 BR BR9915897-3A patent/BR9915897A/pt not_active IP Right Cessation
- 1999-12-02 CN CN99813646A patent/CN1348498A/zh active Pending
- 1999-12-02 AU AU15646/00A patent/AU772033B2/en not_active Ceased
- 1999-12-02 CZ CZ20011909A patent/CZ20011909A3/cs unknown
- 1999-12-02 WO PCT/FR1999/002995 patent/WO2000032803A2/fr not_active Application Discontinuation
- 1999-12-02 EP EP99958234A patent/EP1137793A2/fr not_active Withdrawn
- 1999-12-02 KR KR1020017006897A patent/KR20010101116A/ko not_active Application Discontinuation
- 1999-12-02 HU HU0200345A patent/HUP0200345A3/hu unknown
-
2001
- 2001-05-31 NO NO20012684A patent/NO20012684L/no not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996021036A2 (fr) * | 1994-12-30 | 1996-07-11 | Chiron Viagene, Inc. | Agents de concentration d'acide nucleique ayant une immunogenicite reduite |
WO1996025508A1 (fr) * | 1995-02-17 | 1996-08-22 | Rhone-Poulenc Rorer S.A. | Compositions contenant des acides nucleiques, preparation et utilisation |
WO1998006869A1 (fr) * | 1996-08-14 | 1998-02-19 | The Children's Hospital Of Philadelphia | Vehicules non viraux a utiliser dans le transfert genique |
Non-Patent Citations (4)
Title |
---|
DATABASE CHEMICAL ABSTRACTS [en ligne] abstract no. 126:207866, ERBACHER ET AL: "THE REDUCTION OF THE POSITIVE CHARGES OF POLYLYSINE BY PARTIAL GLUCONOYLATION INCREASES THE TRANSFECTION EFFICIENCY OF POLYLYSINE/DNA COMPLEXES" XP002116398 & BIOCHIM. BIOPHYS. ACTA, vol. 1324, no. 1, 1997, pages 27-36, * |
DATABASE MEDLINE [en ligne] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; abstract 1999129193, GOULA ET AL: "POLYETHYLENIMINE-BASED INTRAVENOUS DELIVERY OF TRANSGENES TO MOUSE LUNG" XP002116399 & GENE THERAPY, vol. 5, no. 9, septembre 1998 (1998-09), pages 1291-1295, * |
DATABASE MEDLINE [en ligne] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; ABSTRACT 96200295, OKU ET AL: "EFFECT OF SERUM PROTEIN BINDING ON REAL-TIME TRAFFICKING OF LIPOSOMES WITH DIFFERENT CHARGES ANALYZED BY POSITRON EMISSION TOMOGRAPHY" XP002116400 & BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1280, no. 1, 3 avril 1996 (1996-04-03), pages 149-154, * |
FUHRHOP J -H ET AL: "BOLAAMPHIPHILES WITH MANNOSE- AND TETRAALKYLAMMONIUM HEAD GROUPS ASCOATINGS FOR NUCLEIC ACIDS AND POSSIBLE REAGENTS FOR TRANSFECTIONS" CHEMISTRY AND PHYSICS OF LIPIDS, vol. 43, 1 avril 1987 (1987-04-01), pages 193-213, XP000562618 ISSN: 0009-3084 * |
Also Published As
Publication number | Publication date |
---|---|
HUP0200345A3 (en) | 2003-12-29 |
KR20010101116A (ko) | 2001-11-14 |
IL142704A0 (en) | 2002-03-10 |
HUP0200345A2 (hu) | 2002-05-29 |
CA2353576A1 (fr) | 2000-06-08 |
NO20012684L (no) | 2001-07-30 |
BR9915897A (pt) | 2001-08-21 |
EP1137793A2 (fr) | 2001-10-04 |
NO20012684D0 (no) | 2001-05-31 |
AU1564600A (en) | 2000-06-19 |
CN1348498A (zh) | 2002-05-08 |
AU772033B2 (en) | 2004-04-08 |
CZ20011909A3 (cs) | 2001-09-12 |
PL348513A1 (en) | 2002-06-03 |
JP2002531468A (ja) | 2002-09-24 |
WO2000032803A3 (fr) | 2000-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0796240B1 (fr) | Lipopolyamines comme agents de transfection et leurs applications pharmaceutiques | |
CA2290664C (fr) | Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules | |
FR2759382A1 (fr) | Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique | |
EP0986568B1 (fr) | Nouvelle classe d'agents transfectants cationiques des acides nucleiques | |
EP1317439B1 (fr) | Composes acidosensibles, leur preparation et utilisations | |
WO2000032803A2 (fr) | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations | |
US6812218B2 (en) | Lipid derivatives of polythiourea | |
EP1430074B1 (fr) | Derives lipidiques d'aminoglycosides-pour la transfection | |
FR2829136A1 (fr) | Derives lipidiques d'aminoglycosides | |
CA2446951C (fr) | Derives lipidiques de polythiouree | |
FR2786700A1 (fr) | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations | |
WO1999051581A1 (fr) | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications | |
FR2777017A1 (fr) | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications | |
MXPA01005457A (es) | Nuevos agentes de transferencia de los acidos nucleicos composiciones que los contienen y sus usos | |
FR2813605A1 (fr) | Composes acidosensibles, leur preparation et utilisations | |
FR2774394A1 (fr) | Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications | |
MXPA99010765A (en) | Novel class of nucleic acid cationic transfecting agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99813646.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2000 15646 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT MA MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT TZ UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT MA MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT TZ UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 142704 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15646/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999958234 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-1909 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/005457 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2353576 Country of ref document: CA Ref document number: 2353576 Country of ref document: CA Kind code of ref document: A Ref document number: 2000 585434 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017006897 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-1909 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1999958234 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017006897 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09857008 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 15646/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999958234 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017006897 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2001-1909 Country of ref document: CZ |